Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment
Authors not listed
Hadassah Medical Organization · 2024
Abstract
The goal of this clinical trial is to learn if the drug Egb761, produced from Ginkgo Biloba extract, works to improve the blood level of a biomarker of Alzheimer's disease, called phosphorylated-tau217 (p-tau217), which serves as a biomarker for disease activity in the brain. The main questions it aims to answer are:
Does drug Egb761 lower the plasma level of p-tau217 in patients with mild cognitive impairment? Does drug Egb761 improve cognitive and behavioral functions in these patients? Does Egb761 affect the blood levels of neurofilament-light (Nfl) and glial-fibrillary-acidic-protein (GFAP), which serve as additional biomarkers for brain disease activity?
Participants will:
Take Egb761 twice daily for 6 months Visit the clinic once every 3 months for checkups and tests Keep a diary of their symptoms
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-10 MST
Cite this
APA
Anonymous. (2024). Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment. <em>Hadassah Medical Organization</em>. https://clinicaltrials.gov/study/NCT07287852
Vancouver
Anonymous. Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment. Hadassah Medical Organization. 2024.
BibTeX
@misc{anon2024IsCere,
title = {Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment},
author = {Anonymous},
journal = {Hadassah Medical Organization},
year = {2024},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Zhejiang Hospital 2025
Open access · US-GOV
A Prospective, Double-blind, Randomized Controlled Clinical Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease
Yanbu Ke 2025
Open access · US-GOV
A Prospective, Double-blind, Randomized Controlled Clinical Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients with Alzheimer's Disease
Peking University First Hospital 2024
Open access · US-GOV
Blood-based Biomarkers for Early Alzheimer's Disease Screening
GlaxoSmithKline 2010
Open access · US-GOV
Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment
Universidad de Almeria 2026
Open access · US-GOV
Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain
Arizona State University 2023
Open access · US-GOV